Travere Therapeutics, Inc.

TVTX Nasdaq SEC CIK 1438533
Follow Travere Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $224.6M +36.2% vs same quarter last year
Net income −$52.3M −303.6% vs same quarter last year
EPS, diluted −$0.55 −296.4% vs same quarter last year
Operating cash flow $98.2M +585.9% vs same quarter last year
Revenue by quarter
$74.8M
$81.7M
$114.4M
$164.9M
$129.7M
$127.2M
$169.6M
$224.6M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$500M−$250M$0$250M$500MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$490.7M−$25.5M
FY24$233.2M−$321.5M
FY23$145.2M−$111.4M
FY22$109.5M−$278.5M
FY21$131.8M−$180.1M
FY20$198.3M−$169.4M
FY19$175.3M−$146.4M
FY18$164.2M−$102.7M
FY17$154.9M−$59.7M
FY16$133.6M−$47.9M
FY15$99.9M$117.2M
FY14$28.2M−$110.9M
FY13$0−$34.6M
FY12$0−$30.3M
FY11$0−$23K
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−400%−200%0%200%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2597.9%−12.8%−5.2%
FY2496.7%−138.9%−137.9%
FY2392.1%−267.2%−76.7%
FY2296%−292.2%−254.4%
FY2197.1%−151.3%−136.6%
FY2096.9%−88.8%−85.4%
FY1997%−78.3%−83.5%
FY1896.6%−48.7%−62.5%
FY1797.7%−34.7%−38.6%
FY1696.6%−43.6%−35.9%
FY1597.8%−50.8%117.4%
FY1498%−283%−393.4%
FY13---
FY12---
FY11---
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0$100MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23−$280.7M
FY22−$186.5M
FY21−$19.9M
FY20−$49.5M
FY19−$58.4M
FY18−$25.7M
FY17$6.5M
FY16−$4.9M
FY15−$1.4M
FY14−$46.5M
FY13−$17.7M
FY12−$2.8M
FY11-
Returned to shareholdersDividends paid and shares bought back
$0$1M$2M$3MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25-
FY24-
FY23-
FY22-
FY21-
FY20-
FY19-
FY18-
FY17-
FY16$0
FY15$0
FY14$2.3M
FY13$958K
FY12-
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Travere Therapeutics
  • Healthcare median
−400%−200%0%200%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearTravere TherapeuticsHealthcare median
FY25−5.2%−30.6%
FY24−137.9%−47%
FY23−76.7%−58%
FY22−254.4%−80.4%
FY21−136.6%−71.8%
FY20−85.4%−62.2%
FY19−83.5%−46.2%
FY18−62.5%−49.6%
FY17−38.6%−45.9%
FY16−35.9%−36%
FY15117.4%−37.8%
FY14−393.4%−35.5%
FY13-−37.1%
FY12-−29.1%
FY11-−27.9%